Harris Hudson, Kittur Javeed
Department of Biomedical Engineering, Gallogly College of Engineering, University of Oklahoma Norman OK USA.
Department of Biomedical Engineering, Gallogly College of Engineering, University of Oklahoma Norman OK USA.
Gene. 2025 Mar 20;942:149257. doi: 10.1016/j.gene.2025.149257. Epub 2025 Jan 18.
CRISPR-Cas9 technology has revolutionized genetic engineering, offering precise and efficient genome editing capabilities. This review explores the application of CRISPR-Cas9 for cystic fibrosis (CF), particularly targeting mutations in the CFTR gene. CF is a multiorgan disease primarily affecting the lungs, gastrointestinal system (e.g., CF-related diabetes (CFRD), CF-associated liver disease (CFLD)), bones (CF-bone disease), and the reproductive system. CF, a genetic disorder characterized by defective ion transport leading to thick mucus accumulation, is often caused by mutations like ΔF508 in the CFTR gene. This review employs a systematic methodology, incorporating an extensive literature search across multiple academic databases, including PubMed, Web of Science, and ScienceDirect, to identify 40 high-quality studies focused on CRISPR-Cas9 applications for CFTR gene editing. The data collection process involved predefined inclusion criteria targeting experimental approaches, gene-editing outcomes, delivery methods, and verification techniques. Data analysis synthesized findings on editing efficiency, off-target effects, and delivery system optimization to present a comprehensive overview of the field. The review highlights the historical development of CRISPR-Cas9, its mechanism, and its transformative role in genetic engineering and medicine. A detailed examination of CRISPR-Cas9's application in CFTR gene correction emphasizes the potential for therapeutic interventions while addressing challenges such as off-target effects, delivery efficiency, and ethical considerations. Future directions include optimizing delivery systems, integrating advanced editing tools like prime and base editing, and expanding personalized medicine approaches to improve treatment outcomes. By systematically analyzing the current landscape, this review provides a foundation for advancing CRISPR-Cas9 technologies for cystic fibrosis treatment and related disorders.
CRISPR-Cas9技术彻底改变了基因工程,提供了精确且高效的基因组编辑能力。本综述探讨了CRISPR-Cas9在囊性纤维化(CF)中的应用,特别是针对CFTR基因中的突变。CF是一种多器官疾病,主要影响肺部、胃肠道系统(如CF相关糖尿病(CFRD)、CF相关肝病(CFLD))、骨骼(CF骨病)和生殖系统。CF是一种遗传性疾病,其特征是离子转运缺陷导致黏液积聚增厚,通常由CFTR基因中的ΔF508等突变引起。本综述采用系统方法,在包括PubMed、科学网和ScienceDirect在内的多个学术数据库中进行广泛的文献检索,以识别40项专注于CRISPR-Cas9在CFTR基因编辑中应用的高质量研究。数据收集过程涉及针对实验方法、基因编辑结果、递送方法和验证技术的预定义纳入标准。数据分析综合了关于编辑效率、脱靶效应和递送系统优化的研究结果,以全面概述该领域。该综述强调了CRISPR-Cas9的历史发展、其机制及其在基因工程和医学中的变革性作用。对CRISPR-Cas9在CFTR基因校正中的应用进行的详细研究强调了治疗干预的潜力,同时解决了脱靶效应、递送效率和伦理考量等挑战。未来的方向包括优化递送系统、整合如引导编辑和碱基编辑等先进编辑工具,以及扩展个性化医疗方法以改善治疗效果。通过系统分析当前的情况,本综述为推进用于囊性纤维化治疗及相关疾病的CRISPR-Cas9技术奠定了基础。